Ollin Biosciences Raises $330M in Series B Funding Round

The round also saw participation from a16z Bio+Health, Blackstone Multi-Asset Investing, Commodore Capital, Canada Pension Plan Investment Board (CPP Investments), RA Capital Management, T. Rowe Price Investment Management, Mubadala Capital and Monograph Capital.

The company plans to use the funding to support global Phase 3 clinical trials of OLN324, a potential VEGF/Ang2 antibody treatment aimed at addressing major causes of vision loss in the $15 billion retina market.

Read More:Coval Raises $28M in Series A Funding Led by Norwest 

In the recently completed JADE clinical study involving 164 patients, OLN324 was compared directly with faricimab (Vabysmo®). The results showed that OLN324 delivered faster and greater improvements in retinal anatomy for both diabetic macular edema (DME) and wet age-related macular degeneration (wAMD), along with numerically higher vision improvements.

Ollin has completed its End-of-Phase 2 meeting with the U.S. FDA and received scientific guidance from the European Medicines Agency (EMA) for its Phase 3 program. The company plans to begin global Phase 3 trials of OLN324 for DME and wAMD in the second half of 2026.

“Ollin is advancing product candidates that have the potential to change the treatment paradigm in vision-threatening diseases significantly,” said Cariad Chester, Managing Partner of TCGX. “OLN324 has been thoughtfully designed through the optimization of its molecular size, potency, and molar dose. In a randomized, head-to-head study, OLN324 generated compelling clinical data that we believe position OLN324 as a best-in-class therapy for one of the largest and most important unmet medical needs in ophthalmology.

“We founded Ollin to challenge the status quo in ophthalmology. We are delighted to welcome a premier syndicate of new and existing investors who share our vision of advancing OLN324 as a potential new standard of care in retinal vascular disease. Their support reflects confidence in the strength of our scientific rationale and clinical data, the significant commercial opportunity in the $15 billion retina market, and the differentiated clinical profile we believe OLN324 can offer physicians and patients,” said Jason Ehrlich, M.D., Ph.D., Co-founder and Chief Executive Officer of Ollin Biosciences.

About Ollin Biosciences

Founded in 2023 by Jason Ehrlich, Ollin Biosciences is a clinical-stage biopharmaceutical company focused on developing and advancing treatments for serious eye diseases that can lead to vision loss. The company combines a promising pipeline of therapies an experienced team, and strong investor support to develop new solution's for ophthalmology patients.

Read More:Runlayer Raises $30M Series A Funding Led by Felicis